Today announced that it has raised $16 million in the original close of a string C financing.

$16 million investment in minute wireless implant technology Remon Medical Technology a privately held medical device company, today announced that it has raised $16 million in the original close of a string C financing. This Series C Round has been led by Lilly Ventures and KBL Healthcare Ventures who were joined by fresh investor Ofer Hi-Tech Group and existing traders Polaris Venture Partners and Concord Ventures read more . Upon this initial close of the financing, Joshua Salisbury, Executive Director, Finance at Eli Lilly and Company, and Michael Kaswan, Managing Director of KBL Healthcare Ventures, have joined the Remon table of directors.

Therefore, the outcomes of this nationwide observational study reflect that which can be expected from the pharmacogenetics of clopidogrel in clinical practice. In summary, in a scholarly research of 2208 sufferers with acute myocardial infarction who were treated with clopidogrel, we evaluated the relationship between genetic determinants of the response to clopidogrel and subsequent cardiovascular events. Genetic variants in CYP2C19 that bring about lack of function were associated with an boost in the chance of loss of life, myocardial infarction, or stroke, among sufferers undergoing PCI especially.. Tabassome Simon, M.D., Ph.D.D., Ph.D., Murielle Mary-Krause, Ph.D., Lina Quteineh, M.D., Elodie Drouet, M.Sc.D., P.